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Background: Traumatic brain injury (TBI) leads to neuronal damage and neu-
rological dysfunction. The aim of our study was to investigate the antioxidative 
effect of honokiol on TBI in rats with biochemical, histopathological and immu-
nohistochemical methods. 
Materials and methods: Sprague–Dawley rats were subjected to TBI with 
a weight-drop device using 300 g/1 m weight/height impact. Forty-five rats were 
divided into three groups as control group, TBI group and TBI + honokiol group 
(5 mg/kg/day, i.p.). Honokiol (5 mg/kg) dissolved in dimethyl sulfoxide (DMSO) 
was intraperitoneally administered to rats for 7 days after the trauma. At the end 
of experiment, blood samples were taken from the animals and analysed with 
various biochemical markers. 
Results: Histopathological examination of the trauma group revealed some de-
generated pyramidal cells, dilatation and congestion in blood vessels, hyperplasia 
in endothelial cells, inflammatory cell infiltration around the vein and disruptions in 
glial extensions. In TBI + honokiol group, pyramidal neurons showed a decrease 
in degeneration, slight dilatation in blood vessels, improvement of endothelial 
cells towards the lumen, and reduction of inflammatory cells in the vessel. In TBI 
+ honokiol group, vascular endothelial growth factor expression was positive in 
the endothelial and few inflammatory cells of the mildly dilated blood vessels. In 
the blood brain barrier deteriorated after trauma, it was observed that the glial 
foot processes were positive expression and extended to the endothelial cells in 
the TBI + honokiol group.
Conclusions: Glial fibrillary acidic protein expression showed a positive reaction 
in these processes. Considering the important role of antioxidants and inflamma-
tory responses in cerebral damage induced by traumatic head injury, honokiol is 
thought to be important in decreasing lipid peroxidation, protecting the membrane 
structure of blood brain barrier, degeneration of neurons and glial cells. (Folia 
Morphol 2019; 78, 4: 684–694)
Key words: traumatic brain injury, honokiol, vascular endothelial growth 
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INTRODUCTION
Traumatic brain injury (TBI) is a health problem 
known as the cause of mortality and disability in 
young people. Primary and secondary injury cascades 
that cause delayed neuronal dysfunction, synapse 
loss and cell death are associated with TBI [1, 39]. 
Secondary damage develops within the minutes to 
days following the primary insult, release of the in-
flammatory mediators, formation of the free radicals, 
excessive release of the neurotransmitters (glutamate 
and aspartate), influx of calcium and sodium ions 
into neurons, and dysfunction of mitochondria [22]. 
At a cellular level, the biphasic nature of secondary 
injury is mediated by numerous disturbed pathways 
which include: excitotoxicity caused by an excess of 
the neurotransmitter glutamate; free radical gener-
ation by dysfunctional mitochondria, causing dam-
age to proteins and phospholipid membranes of 
neurons and glia; the neuroinflammatory response 
which takes place due to both brain parenchyma 
and systemic immunoactivation [22, 31]. Glutamate 
is an excitatory amino acid which is known to play 
a role in the pathological events, increasing brain-
blood barrier permeability and the occurrence of 
oxidant damage. Previous studies have shown that 
glutamate antagonists may be beneficial in several 
conditions, such as ischaemia, sepsis and trauma 
[1, 22]. The neuroinflammation is closely related to 
the overproduction of the reactive oxygen species 
which cause many neuropathologies. Free radicals 
damage various cellular components, including pro-
teins, lipids and deoxyribonucleic acid. Antioxidants 
and anti-inflammatory drugs were widely studied in 
neurotrauma models [31]. After trauma, depending 
on the degree of brain damage, neuroinflammation, 
cerebral oedema and blood-brain barrier fragmenta-
tion occur. Vascular endothelial growth factor (VEGF) 
is a trophic factor that is expressed in the central 
nervous system after injury [10] and induces angio - 
genesis [34]. Inhibition of VEGF expression after trau-
ma may exacerbate neuronal and glial injury [23]. 
However, increased endogenous VEGF interacts with 
ischaemic vessels with its receptors and contributes 
to the deterioration of the blood-brain barrier and 
subsequent leakage [51].
Glial fibrillary acidic protein (GFAP) is an intermedi-
ate filament protein found in the skeleton of astroglia. 
Data from studies have shown that increased local 
tissue GFAP immunoreactivity is a sensitive indicator 
of neuronal damage and its increase is considered to 
be a determinant of reactive astrocytosis. GFAP level 
in blood fluid increases when cerebral tissue or spi-
nal cord cells are damaged due to trauma or disease 
[15, 41, 50]. This marker is in fact an indicator of the 
reaction of astrocytes in the form reactive gliosis.
Honokiol is a natural biphenolic compound that is 
isolated from magnolia bark and has been used in the 
traditional Chinese and Japanese medicine as an anti-
bacterial, antiemetic, antidepressant, antithrombotic, 
and anxiolytic agent. Studies have shown therapeutic 
effects including antioxidative and anti-inflammatory 
activities for honokiol [16, 27, 28].
Traumatic brain injury animal models are im-
portant in developing diagnostic and therapeutic 
strategies for understanding the pathophysiology of 
brain shocks [40]. In this study, antioxidative effects 
of honokiol on neuronal structures and changes in 
blood-brain barrier were investigated in TBI. In this 
study, we aimed to investigate antioxidative effects 
of honokiol on neuronal structures in a TBI model in 
rats with biochemical, histopathological and immu-
nohistochemical methods.
MaTERIalS aND METhODS
Animals
Every single surgical methodology and the con-
sequent care and healing of the animals utilised as 
a part of this investigation were in strict understanding 
with the National Institutes of Health (NIH Publications 
No. 8023, revised 1978) rules for animal care. All tech-
niques performed in this examination were approved 
by the Ethics Committee for Animal Experimentation 
of the Faculty of Medicine at Dicle University, Turkey. 
Male Sprague-Dawley rats (250–280 g) were housed 
in an air-conditioned room with 12-h light and dark 
cycles, where the temperature (23 ± 2°C) and relative 
humidity (65–70%) were kept constant. All rats at the 
end of experiment were healthy and no difference in 
food/water consumption and body weight gain be-
tween experimental and control rats were observed.
Traumatic brain injury model
Sedation procedure. The animals were anes-
thetised by an intraperitoneal injection of 5 mg/kg 
xylazine HCl (Rompun, Bayer Health Care AG, Germa-
ny) and 40 mg/kg ketamine HCl (Ketalar, Pfizer Inc., 
USA), and were allowed to breathe spontaneously. 
A rectal probe was inserted, and the animals were 
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positioned on a heating pad that maintained the body 
temperature at 37°C. 
Three groups (15 rats per group) were arranged 
as below:
 — Control group: Isotonic saline solution (an equal 
volume of honokiol) was administered i.p. for 
7 days;
 — TBI group: The widely used diffuse brain injury 
model described by Marmarou et al. [31] was 
used. Briefly, a trauma device which works by 
dropping a constant weight from a specific height 
through a tube was used. A weight of 300 g was 
dropped from a 1 m height, which can induce mild 
trauma, as shown by Ucar et al. [46];
 — TBI + honokiol group: Honokiol (5 mg/kg; Sig-
ma-Aldrich Inc., St. Louis, MO, USA) dissolved in 
dimethyl sulfoxide (DMSO) was intraperitoneally 
administered for 7 days after the trauma. After 
7 days, all animals were sacrificed by an intraperi-
toneal injection of 5 mg/kg xylazine HCl (Rompun, 
Bayer HealthCare AG, Germany) and 40 mg/kg 
ketamine HCl (Ketalar, Pfizer Inc., USA). After TBI, 
blood samples were taken from the animals and 
analysed with various biochemical markers. Then, 
parietal lobe of the brain cortex were rapidly re-
moved. For the histological examination, brain 
tissues were fixed in 10% formaldehyde solu-
tion, post-fixed in 70% alcohol, and embedded 
in paraffin wax. The sections were stained with 
haematoxylin-eosin (H&E).
Malondialdehyde and glutathione  
peroxidase assays  
Tissue samples were homogenised with ice-cold 
150 mM KCl for the determination of malondialde-
hyde (MDA) and glutathione peroxidase (GSH-Px) 
levels. The MDA levels were assayed for products 
of lipid peroxidation, and the results are expressed 
as nmol MDA/g tissue [42]. Glutathione was 
determined by the spectrophotometric method, 
which was based on the use of Ellman’s reagent, 
and the results are expressed as μmol glutathione/g 
tissue [38].
Myeloperoxidase assay
Myeloperoxidase (MPO) activity in tissues was 
measured by a procedure similar to that described 
by Hillegas et al. [17]. Myeloperoxidase activity is 
expressed as U/g tissue.
Evans blue assay for blood-brain  
barrier permeability 
To evaluate the blood–brain barrier integrity, 
Evans blue (EB) dye was used as a marker of albumin 
extravasation [14]. EB was expressed as μg/mg of 
brain tissue against a standard curve.
Immunohistochemical technique
Formaldehyde-fixed tissue was embedded in paraf-
fin wax for further immunohistochemical examination. 
Sections were deparaffinised in xylene. Antigen retrieval 
process was performed twice in citrate buffer solution 
(pH: 6.0), first for 7 min, and second for 5 min, boiled in 
a microwave oven at 700 W. They were allowed to cool 
to room temperature for 30 min and washed twice in 
distilled water for 5 min. Endogenous peroxidase activity 
was blocked in 0.1% hydrogen peroxide for 20 min. Ul-
tra V block (Cat. No:85-9043, Invitrogen, Carlsbad, CA, 
USA) was applied for 10 min prior to the overnight ap-
plication of primary antibodies VEGF antibody (Cat. No: 
RB-222-P0) (1:100 dilution), GFAP antibody (1:100 dilu-
tion) (Cat. No: PA3-067, Invitrogen, Carlsbad, CA, USA). 
Secondary antibody (Cat. No: 85- 9043, Invitrogen, 
Carlsbad, CA, USA) was applied for 20 min. Slides were 
then exposed to streptavidin–peroxidase for 20 min. 
Chromogen diaminobenzidine (DAB) (Invitrogen, Cat. 
No: 34002 Carlsbad, CA, USA) was used. Control slides 
were prepared as mentioned above, but omitting the 
primary antibodies. After counterstaining with hae-
matoxylin, and washing in tap water for 8 min and 
in distilled water for 10 min, the slides were mounted 
with Entellan.
Statistical analysis
Statistical analysis of biochemical findings was car-
ried out using GraphPad Prism 4.0 software (GraphPad 
Software, 2003, San Diego, CA, USA). All data are 
presented as mean ± standard deviation (SD). Groups 
of data were compared with an analysis of variance 
(ANOVA) followed by Tukey’s multiple comparison 
tests. Values of p < 0.001 and p < 0.01 were consid-
ered as statistically significant (Fig. 1). For the statistical 
analysis of VEGF and GFAP expression, Kruskal-Wallis 
and Mann-Whitney U non-parametric statistical tests 
were used in the intergroup comparisons depending 
on the variables and the results were given as the mean 
± SD and mean rank. And, the results were considered 
statistically significant for p = 0 with Kruskal-Wallis 
test and p < 0.05 with Mann-Whitney U test (Table 1).
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RESUlTS
Biochemical findings
The following biochemical parameters were com-
pared between groups (Fig. 1).
Tissue MDA levels 
Malondialdehyde values in the trauma (TBI) group 
were significantly higher than those of the control 
group (p < 0.001), while the TBI + honokiol group 
had significantly lower levels than those of the trauma 
(TBI) group (p < 0.001).
Tissue GSH-Px levels 
Glutathione peroxidase levels of the control group 
were significantly higher than those of the trauma 
group (p < 0.01), while those of the TBI + honokiol 
group were also significantly higher than those of 
the trauma group (p < 0.01).
Tissue MPO activity
Myeloperoxidase levels of the control group were 
significantly lower than those of the trauma group 
(p < 0.01), while those of the TBI + honokiol group 
were also significantly lower than those of the trauma 
group (p < 0.01).
Evans blue assay for blood-brain barrier  
permeability
Blood–brain barrier permeability values of the 
control group were significantly lower than those of 
Figure 1. Biochemical results relevant to the study groups; abbreviations — see text.
Table 1. Histopathological scoring of vascular endothelial growth factor (VEGF) and glial fibrillary acidic protein (GFAP) expressions
Histopathological scoring of control and experimental groups
Parameter Groups N Mean ± SD Mean rank Kruskal-Wallis 
test value
Mann-Whitney U comparisons  
for groups (p < 0.05)
VEGF expression (1) Control 15 1.81 ± 0.65 17.08 (2)**
(2) TBI 15 3.12 ± 0.71 30.12 19.397; *p = 0 (1)** (3)**
(3) TBI + honokiol 15 2.00 ± 0.73 44.30 (2)**
GFAP expression (1) Control 15 3.31 ± 0.60 10.50 (2)** 
(2) TBI 15 1.37 ± 0.61 33.65 34.034; *p = 0 (1)** (3)**
(3) TBI + honokiol 15 3.06 ± 044 47.35 (2)**
Data are expressed as the mean ± standard deviation (SD) and mean rank (*p = 0 with Kruskal-Wallis test, **p < 0.05 with Mann-Whitney U test, * and ** — statistically significant 
result). The quantification of all parameters: 0 — no change, 1 — too week, 2 — week, 3 — middle, 4 — strong (Scoring was determined by examining histological parameters in  
15 different regions within the microscope field); TBI — traumatic brain injury
0
0
0
0
Control
Control
Control
Control
TBI
TBI
TBI
TBI
MDA [nmol/g]
MPO [U/g]
GSH [mmol/g]
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the trauma group (p < 0.001), while those of the TBI 
+ honokiol group were also significantly lower than 
those of the trauma group (p < 0.001).
Histopathologic findings
When brain cortex of the control group was exam-
ined, the pyramidal neurons were polyhedral and had 
chromatin-rich nuclei. Glial cells were observed with 
small round nuclei and distributed solitary.
The lumen of the capillary vessels in the cortex was 
regular and the endothelial cells were flat (Fig. 2a). His-
topathological examination of the TBI group revealed 
some degenerated pyramidal cells, pyknotic nuclei, 
dilated and congested blood vessels, hyperplasia in en-
dothelial cells, inflammatory cell infiltration around the 
vein and disruptions in glial extensions (Fig. 2b). In the 
histopathological examination of the TBI + honokiol 
group, we observed a decrease in degenerated pyram-
idal neurons, polygonal and dense-chromatin nuclei, 
slight dilated blood vessels and flattened endothelial 
cells towards the lumen and decrease in inflammatory 
cells around the vessel (Fig. 2c).
Immunohistochemical findings
Vascular endothelial growth factor expression 
in the capillary endothelial and some glial cells in 
the cortex showed a positive reaction in the control 
group sections (Fig. 3a). In the TBI group, glial cells 
around some degenerated neurons, dilated capil-
lary endothelial cells and vascular inflammatory cells 
showed increased VEGF expression (Fig. 3b). In the 
TBI + honokiol group, VEGF expression was positive 
in the endothelial and few inflammatory cells of the 
mildly dilated blood vessels (Fig. 3c). When GFAP 
expression was examined in the control group, it 
was observed that the glial foot processes around 
the capillary vein covered the basement membrane 
like a meshwork and were firmly bound to the en-
dothelial cells, and the expression of GFAP protein 
was significant (Fig. 3d). In the TBI group, loss of 
glial extensions was observed with deterioration of 
the glial food processes around the dilated capillary 
vessels. GFAP positive expression was observed in the 
short thick extensions away from the vessels (Fig. 3e). 
A significant increase in GFAP expression was observed 
in the glial food processes that covered the lumen of 
regular capillaries in the TBI + honokiol group (Fig. 3f).
DISCUSSION
Shortly after TBI, lack of blood flow causes necrotic 
neuronal death; however, greater loss of apoptotic 
Figure 2. a. Haematoxylin and eosin (H&E) staining, original mag-
nification ×40 (Control group). Normal appearance of regular cells 
and vascular structures in brain cortex; b. H&E staining, original 
magnification ×40 (TBI group). Dilation in blood vessels and  
haemorrhage (yellow arrow), degenerative changes in some neurons,  
hyperplasia in endothelial cells (red arrow), inflammatory cell  
infiltration around blood vessels (green arrow) and disruptions in 
glial extensions; c. H&E staining, original magnification ×40  
(TBI + honokiol group). Reduction in vascular dilatation (yellow 
arrow), flat endothelial cells towards the lumen, and decrease in 
inflammatory cells around the blood vessel (green arrow), regular 
structure of the nucleus and cytoplasm in neurons and glial cells; 
TBI — traumatic brain injury. 
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Figure 3. a. Vascular endothelial growth factor (VEGF) immunostaining, original magnification ×40 (Control group). VEGF expression in the 
capillary endothelial (yellow arrow), and some glial cells in the cortex; a*. Negative control, haematoxylin staining, original magnification ×40;  
b. VEGF immunostaining, original magnification ×40 (TBI group). An increase in VEGF expression glial cells around some degenerated neu-
rons and dilated capillary endothelial and vascular inflammatory cells (yellow arrow); b*. Negative control, haematoxylin staining, original 
magnification ×40; c. VEGF immunostaining, original magnification ×40 (TBI + honokiol group). Positive VEGF expression in the endothelial 
and few inflammatory cells of the mildly dilated blood vessels (yellow arrow); c*. Negative control, haematoxylin staining, original magnifica-
tion ×40; TBI — traumatic brain injury.
690
Folia Morphol., 2019, Vol. 78, No. 4
Figure 3. d. Glial fibrillary acidic protein (GFAP) immunostaining, original magnification ×40 (Control group). Positive GFAP expression in glial 
food processes around the capillary vessel (yellow arrow); d*. Negative control, haematoxylin staining, original magnification ×40; e. GFAP 
immunostaining, original magnification ×40 (TBI group). Loss and degeneration in glial food processes around the dilated capillary vessels, 
positive GFAP expression (yellow arrows); e*. Negative control, haematoxylin staining, original magnification ×40; f. GFAP immunostaining, 
original magnification ×40 (TBI + honokiol group). An increase GFAP expression in glial food processes (yellow arrows); f*. Negative con-
trol, haematoxylin staining, original magnification ×40; TBI — traumatic brain injury.
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neurons may then occur after secondary injury of 
hypoxia/ischaemia and oxidative stress and inflam-
mation [8, 9, 12].
Previous studies have shown that a variety of 
pathological factors, such as oxidative stress, the 
inflammatory response and apoptosis, are involved 
in secondary brain injury after TBI. Furthermore, early 
interventions to reduce the level of oxidative stress 
and the extent of the inflammatory response can 
significantly reduce the extent of TBI [13]. Baloğlu et 
al. [2] observed a significant increase in MDA levels in 
spinal cord injury and a significant decrease in level 
of GSH and MPO. They have observed degenerative 
changes in some multipolar and bipolar nerve cells 
and pyknotic changes in the nucleus of glial cells.
Traumatic brain injury initiates a neuroinflam-
matory cascade characterised by microglial activa-
tion and increased production of proinflammatory 
cytokines [24]. TBI often promotes disruption of 
blood–brain barrier integrity and the neurovascular 
unit, which can result in vascular leakage, oedema, 
haemorrhage, and hypoxia. Other pathologic mech-
anisms include cell death within the meninges and 
brain parenchyma, stretching and tearing of axonal 
fibres, and disruptions at the junctions between white 
and grey matter, stemming from rotational forces 
that cause shearing injuries [3]. In this study, histo-
pathological examination of the TBI group revealed 
some degenerated pyramidal cells, pyknotic nuclei, 
dilated and congested blood vessels, hyperplasia in 
endothelial cells, inflammatory cell infiltration around 
the vein and disruptions in glial extensions (Fig. 2b). 
In the TBI + honokiol group, pyramidal neurons were 
less degenerated, also there were slight dilatation 
of blood vessels, improvement of endothelial cells 
towards the lumen, and reduction of inflammatory 
cells in the vessel (Fig. 2c). Feng et al. [11] reported 
that TBI can result in synapse loss or damage and 
may contribute to observed behavioural, cognitive, 
and neurological disorders.
Vascular endothelial growth factor is effective 
on vascular and neural development. It was thought 
that brain oedema was dominant because of the 
increase in VEGF expression and blood–brain barrier 
destruction in the post-traumatic contusion stage 
[6, 43]. Lenzlinger et al. [23] found that inhibition of 
VEGF significantly reduced regional cerebral oedema 
in TBI rats. Krum and Khaibullina [19] showed that 
inhibition of VEGF signals, including VEGF-R1 recep-
tors, decreased the numbers of reactive astrocytes 
and prevented glial scar formation in TBI models. In 
our TBI group, an increase in VEGF expression levels, 
vascular permeability, and rapid interaction of VEGF 
receptors in endothelial cells led to the destruction 
of vascular wall in the blood–brain barrier and the 
formation of oedema. The neuroprotective function 
of VEGF is thought to be due to a combination of 
direct neuroprotective effects and stimulation of an-
giogenesis. GFAP, a brain-specific protein that acts as 
the major integral component of the cell skeleton of 
astrocytes, GFAP after brain injury discharges the brain 
cells into the interstitial fluid in the environment and 
causes deterioration in the blood-brain barrier [32]. 
An increase in GFAP expression is a cardinal feature of 
many pathological conditions of the central nervous 
system and astrocytes. Increasing numbers of GFAP 
positive expression astroglia cells following TBI have 
been described in several experimental studies in an-
imals. GFAP was positively expressed in the normal 
brain tissue, processes in astrocytes around blood–
brain barrier rupture was defined as significant GFAP 
expression [15, 50]. Özevren et al. [37] showed that 
glial food processes around the blood vessels were de-
creased and GFAP expression was positive after trauma. 
Honokiol with its antioxidant effects was shown 
to provide protection against cerebral ischae-
mia-reperfusion (I/R) injuries and dermatological 
disorders [52]. It has been reported that honoki-
ol can provide potential support to clinical trials 
in ischaemia treatment by passing through the 
blood–brain barrier in low-dose long-term treat-
ments [48]. Honokiol has been reported to protect 
the rat brain from focal cerebral ischaemia-reperfu-
sion (I/R) injury by inhibiting neutrophil infiltration 
and production of reactive oxygen species [28]. In 
a similar way to our study, they investigated the ef-
fects of honokiol, a cell cycle inhibitor, on neuronal 
damage reduction and functional recovery after TBI 
in rats. They demonstrated that honokiol, adminis-
tered intravenously, has a strong neuroprotective 
effect against sensorimotor and cognitive deficits 
after TBI, which is highly associated with the survival 
of increased neurons. It has been suggested that 
the neurocompatibility mediated by honokiol after 
TBI may affect the molecular mechanism due to 
suppression of over-activated cell cycle [47]. Talerek 
et al. [45] have made a comprehensive assessment 
of the potential molecular mechanisms of action 
that are considered as a promising agent in the 
treatment and management of neurodegenerative 
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diseases concerning the neuroprotective effects of 
honokiol [45]. In the experimental studies, it was 
stated that honokiol plays an active agent role in 
the central nervous system. Antioxidant activity, 
inhibition of excitotoxicity; and cell signalling in 
neuroinflammation has been shown as evidences on 
its neuroprotective activity [20, 21, 25, 26, 48, 49]. 
In studies of experimental and human cell culture, 
it has been reported that honokiol can reduce oxi-
dative stress parameters in several catabolic tissues 
such as liver [44], endothelial cells [36], muscle tis-
sue [5], heart or kidney [30]. However, there is little 
information in studies demonstrating the oxidative 
inhibition of honokoil in the central nervous system. 
Chuang et al. [7] studied the effect of honokiol on 
oxidative stress and inflammation in neural and 
microglial cells. They investigated the oxidative 
and inflammatory responses of these isomers in 
microglial cells activated by interferon-gamma 
and lipopolysaccharide in suppressing oxidative 
stress in neuronal stimulated neurons by ionotropic 
glutamate receptor agonist N-methyl-D-aspartate. 
And, they also investigated the mechanism and 
signalling pathways involved in cytokine-induced 
production of reactive oxygen species in microglial 
cells. Their results of microglial cells also demon-
strated the important role of interferon-gamma in 
stimulating signalling pathways involving activation 
of extracellular signal-regulated protein kinases 1 
and 2, reactive oxygen species and nitric oxide. 
Studies have shown that honokiol inhibits reactive 
oxygen species in neutrophils [28] and suppresses 
the lipopolysaccharide-induced tumour necrosis 
factor alpha and nitric oxide expression in mac-
rophages [18]. In addition, some authors suggest 
that honokiol can inhibit nuclear factor kappa light 
chain enhancer of activated B cells activation in 
mouse B cells [31], macrophages [4] and lipopol-
ysaccharide-induced microglia cells [52]. It is also 
believed that honokiol can selectively modulate the 
phosphoinositide 3-kinase/Akt pathway [18, 35, 53]. 
CONClUSIONS
The neuroprotective effect of honokiol was found 
to be parallel to the reduction of lipid peroxidation 
and inhibition of inflammatory cell in cerebral tissue. 
After trauma, the structure of glial food processes 
deteriorates along with the increase in inflamma-
tion towards endothelial cells. Due to the effect of 
honokiol, the improvement of vascular wall due to 
decreased inflammation in this region and the regular 
distribution of glial food processes define the anti-
oxidative development. Considering the important 
role of antioxidants and inflammatory responses in 
cerebral damage induced by traumatic head injury, 
honokiol is thought to be important in decreasing li-
pid peroxidation and protecting the membrane struc-
ture of blood–brain barrier, degeneration of neurons 
and glial cells.
REFERENCES
1. Baldwin SA, Gibson T, Callihan CT, et al. Neuronal cell 
loss in the CA3 subfield of the hippocampus follow-
ing cortical contusion utilizing the optical disector 
method for cell counting. J Neurotrauma. 1997; 14(6): 
385–398, doi:  10.1089/neu.1997.14.385, indexed in 
Pubmed: 9219853.
2. Baloğlu M, Çetin A, Tuncer MC. Neuroprotective effects 
of Potentilla fulgens on spinal cord injury in rats: an im-
munohistochemical analysis. Folia Morphol. 2018 [Epub 
ahead of print], doi: 10.5603/FM.a2018.0050, indexed in 
Pubmed: 30402877.
3. Blennow K, Hardy J, Zetterberg H. The neuropathology 
and neurobiology of traumatic brain injury. Neuron. 2012; 
76(5): 886–899, doi: 10.1016/j.neuron.2012.11.021, in-
dexed in Pubmed: 23217738.
4. Chao LK, Liao PC, Ho CL, et al. Anti-inflammatory bioac-
tivities of honokiol through inhibition of protein kinase C, 
mitogen-activated protein kinase, and the NF-kappaB 
pathway to reduce LPS-induced TNFalpha and NO ex-
pression. J Agric Food Chem. 2010; 58(6): 3472–3478, 
doi: 10.1021/jf904207m, indexed in Pubmed: 20192217.
5. Chiang J, Shen YC, Wang YH, et al. Honokiol protects 
rats against eccentric exercise-induced skeletal muscle 
damage by inhibiting NF-kappaB induced oxidative stress 
and inflammation. Eur J Pharmacol. 2009; 610(1-3): 
119–127, doi: 10.1016/j.ejphar.2009.03.035, indexed in 
Pubmed: 19303869.
6. Chodobski A, Chung I, Koźniewska E, et al. Early neutro-
philic expression of vascular endothelial growth factor 
after traumatic brain injury. Neuroscience. 2003; 122(4): 
853–867, doi:  10.1016/j.neuroscience.2003.08.055, in-
dexed in Pubmed: 14643756.
7. Chuang DY, Chan MH, Zong Y, et al. Magnolia polyphe-
nols attenuate oxidative and inflammatory responses 
in neurons and microglial cells. J Neuroinflammation. 
2013; 10: 15, doi: 10.1186/1742-2094-10-15, indexed in 
Pubmed: 23356518.
8. Coles JP. Regional ischemia after head injury. Curr Opin 
Crit Care. 2004; 10(2): 120–125.
9. Diaz-Arrastia R, Kochanek PM, Bergold P, et al. Pharmaco-
therapy of traumatic brain injury: state of the science and 
the road forward: report of the Department of Defense 
Neurotrauma Pharmacology Workgroup. J Neurotrauma. 
2014; 31(2): 135–158, doi: 10.1089/neu.2013.3019, in-
dexed in Pubmed: 23968241.
10. Dore-Duffy P, Wang X, Mehedi A, et al. Differential 
expression of capillary VEGF isoforms following trau-
matic brain injury. Neurol Res. 2007; 29(4): 395–403, 
doi:  10.1179/016164107X204729, indexed in Pu-
bmed: 17626736.
693
A. Çetin, E. Deveci, Expression of VEGF and GFAP in a rat model of traumatic brain injury treated with honokiol
11. Feng Y, Cui Y, Gao JL, et al. Neuroprotective effects of 
resveratrol against traumatic brain injury in rats: In-
volvement of synaptic proteins and neuronal autophagy. 
Mol Med Rep. 2016; 13(6): 5248–5254, doi: 10.3892/
mmr.2016.5201, indexed in Pubmed: 27122047.
12. Greve MW, Zink BJ. Pathophysiology of traumatic brain 
injury. Mt Sinai J Med. 2009; 76(2): 97–104, doi: 10.1002/
msj.20104, indexed in Pubmed: 19306379.
13. Gyoneva S, Ransohoff RM. Inflammatory reaction after 
traumatic brain injury: therapeutic potential of tar-
geting cell-cell communication by chemokines. Trends 
Pharmacol Sci. 2015; 36(7): 471–480, doi:  10.1016/j.
tips.2015.04.003, indexed in Pubmed: 25979813.
14. Hakan T, Toklu HZ, Biber N, et al. Effect of COX-2 inhib-
itor meloxicam against traumatic brain injury-induced 
biochemical, histopathological changes and blood-brain 
barrier permeability. Neurol Res. 2010; 32(6): 629–635, 
doi: 10.1179/016164109X12464612122731, indexed in 
Pubmed: 19660237.
15. Hausmann R, Riess R, Fieguth A, et al. Immunohisto-
chemical investigations on the course of astroglial GFAP 
expression following human brain injury. Int J Legal Med. 
2000; 113(2): 70–75, indexed in Pubmed: 10741479.
16. Hayashi T, Saito A, Okuno S, et al. Damage to the endo-
plasmic reticulum and activation of apoptotic machinery 
by oxidative stress in ischemic neurons. J Cereb Blood 
Flow Metab. 2005; 25(1): 41–53, doi:  10.1038/sj.jcb-
fm.9600005, indexed in Pubmed: 15678111.
17. Hillegass LM, Griswold DE, Brickson B, et al. Assess-
ment of myeloperoxidase activity in whole rat kidney. 
J Pharmacol Methods. 1990; 24(4): 285–295, indexed in 
Pubmed: 1963456.
18. Kim BH, Cho JY. Anti-inflammatory effect of honokiol is 
mediated by PI3K/Akt pathway suppression. Acta Phar-
macol Sin. 2008; 29(1): 113–122, doi:  10.1111/j.1745-
7254.2008.00725.x, indexed in Pubmed: 18158873.
19. Krum JM, Khaibullina A. Inhibition of endogenous VEGF 
impedes revascularization and astroglial proliferation: 
roles for VEGF in brain repair. Exp Neurol. 2003; 181(2): 
241–257, doi: 10.1016/s0014-4886(03)00039-6, indexed 
in Pubmed: 12781997.
20. Kuribara H, Kishi E, Kimura M, et al. Comparative as-
sessment of the anxiolytic-like activities of honokiol and 
derivatives. Pharmacol Biochem Behav. 2000; 67(3): 
597–601, doi: 10.1016/s0091-3057(00)00401-9, indexed 
in Pubmed: 11164091.
21. Kuribara H, Stavinoha WB, Maruyama Y. Honokiol, a pu-
tative anxiolytic agent extracted from magnolia bark, has 
no diazepam-like side-effects in mice. J Pharm Pharmacol. 
1999; 51(1): 97–103, indexed in Pubmed: 10197425.
22. Lee S, Park S, Won J, et al. The Incremental Induction of 
Neuroprotective Properties by Multiple Therapeutic Strate-
gies for Primary and Secondary Neural Injury. Int J Mol Sci. 
2015; 16(8): 19657–19670, doi: 10.3390/ijms160819657, 
indexed in Pubmed: 26295390.
23. Lenzlinger PM, Saatman KE, Hoover RC, et al. Inhibition of 
vascular endothelial growth factor receptor (VEGFR) sign-
aling by BSF476921 attenuates regional cerebral edema 
following traumatic brain injury in rats. Restor Neurol Neu-
rosci. 2004; 22(2): 73–79, indexed in Pubmed: 15272142.
24. Lim SW, Wang CC, Wang YH, et al. Microglial activation 
induced by traumatic brain injury is suppressed by postin-
jury treatment with hyperbaric oxygen therapy. J Surg Res. 
2013; 184(2): 1076–1084, doi: 10.1016/j.jss.2013.04.070, 
indexed in Pubmed: 23726237.
25. Lin JW, Chen JT, Hong CY, et al. Honokiol traverses the 
blood-brain barrier and induces apoptosis of neuroblas-
toma cells via an intrinsic bax-mitochondrion-cytochrome 
c-caspase protease pathway. Neuro Oncol. 2012; 14(3): 
302–314, doi:  10.1093/neuonc/nor217, indexed in Pu-
bmed: 22259050.
26. Lin YR, Chen HH, Lin YC, et al. Antinociceptive actions of 
honokiol and magnolol on glutamatergic and inflamma-
tory pain. J Biomed Sci. 2009; 16: 94, doi: 10.1186/1423-
0127-16-94.
27. Liou KT, Lin SM, Huang SS, et al. Honokiol ameliorates 
cerebral infarction from ischemia-reperfusion injury in 
rats. Planta Med. 2003; 69(2): 130–134, doi: 10.1055/s-
2003-37707, indexed in Pubmed: 12624817.
28. Liou KT, Shen YC, Chen CF, et al. Honokiol protects rat 
brain from focal cerebral ischemia-reperfusion injury 
by inhibiting neutrophil infiltration and reactive oxygen 
species production. Brain Res. 2003; 992(2): 159–166, 
doi: 10.1016/j.brainres.2003.08.026, indexed in Pubmed: 
14625055.
29. Liou KT, Shen YC, Chen CF, et al. The anti-inflammatory 
effect of honokiol on neutrophils: mechanisms in the 
inhibition of reactive oxygen species production. Eur 
J Pharmacol. 2003; 475(1-3): 19–27, doi: 10.1016/s0014-
2999(03)02121-6, indexed in Pubmed: 12954355.
30. Lo YC, Teng CM, Chen CF, et al. Magnolol and honokiol 
isolated from Magnolia officinalis protect rat heart mito-
chondria against lipid peroxidation. Biochem Pharmacol. 
1994; 47(3): 549–553, doi: 10.1016/0006-2952(94)90187-
2, indexed in Pubmed: 8117323.
31. Marmarou A, Foda MA, van den Brink W, et al. A new 
model of diffuse brain injury in rats. Part I: Pathophys-
iology and biomechanics. J Neurosurg. 1994; 80(2): 
291–300, doi:  10.3171/jns.1994.80.2.0291, indexed in 
Pubmed: 8283269.
32. Missler U, Wiesmann M, Wittmann G, et al. Measurement 
of glial fibrillary acidic protein in human blood: analytical 
method and preliminary clinical results. Clin Chem. 1999; 
45(1): 138–141, indexed in Pubmed: 9895354.
33. Munroe ME, Arbiser JL, Bishop GA. Honokiol, a natural 
plant product, inhibits inflammatory signals and allevi-
ates inflammatory arthritis. J Immunol. 2007; 179(2): 
753–763, doi: 10.4049/jimmunol.179.2.753, indexed in 
Pubmed: 17617564.
34. Nag S, Takahashi JL, Kilty DW. Role of vascular endothelial 
growth factor in blood-brain barrier breakdown and angi-
ogenesis in brain trauma. J Neuropathol Exp Neurol. 1997; 
56(8): 912–921, doi:  10.1097/00005072-199708000-
00009, indexed in Pubmed: 9258261.
35. Nakano N, Matsuda S, Ichimura M, et al. PI3K/AKT signa-
ling mediated by G protein-coupled receptors is involved 
in neurodegenerative Parkinson’s disease (Review). 
Int J Mol Med. 2017; 39(2): 253–260, doi:  10.3892/
ijmm.2016.2833, indexed in Pubmed: 28000847.
36. Ou HC, Chou FP, Lin TM, et al. Protective effects of honokiol 
against oxidized LDL-induced cytotoxicity and adhesion 
molecule expression in endothelial cells. Chem Biol Inter-
act. 2006; 161(1): 1–13, doi: 10.1016/j.cbi.2006.02.006, 
indexed in Pubmed: 16580656.
694
Folia Morphol., 2019, Vol. 78, No. 4
37. Özevren H, Irtegün S, Deveci E, et al. Neuroprotective 
effects of Potentilla fulgens on traumatic brain injury in 
rats. Anal Quant Cytol Histol. 2017; 39: 35–44.
38. Preston GW, Phillips DH. Quantification of a peptide 
standard using the intrinsic fluorescence of tyrosine. Anal 
Bioanal Chem. 2016; 408(9): 2187–2193, doi: 10.1007/
s00216-016-9334-1, indexed in Pubmed: 26879647.
39. Scheff SW, Price DA, Hicks RR, et al. Synaptogenesis in the 
hippocampal CA1 field following traumatic brain injury. 
J Neurotrauma. 2005; 22(7): 719–732, doi:  10.1089/
neu.2005.22.719, indexed in Pubmed: 16004576.
40. Shultz SR, McDonald SJ, Vonder Haar C, et al. The po-
tential for animal models to provide insight into mild 
traumatic brain injury: Translational challenges and strat-
egies. Neurosci Biobehav Rev. 2017; 76(Pt B): 396–414, 
doi:  10.1016/j.neubiorev.2016.09.014, indexed in Pu-
bmed: 27659125.
41. Sofroniew MV, Vinters HV. Astrocytes: biology and pathol-
ogy. Acta Neuropathol. 2010; 119(1): 7–35, doi: 10.1007/
s00401-009-0619-8, indexed in Pubmed: 20012068.
42. Sohrab G, Angoorani P, Tohidi M, et al. Pomegranate 
(Punicagranatum) juice decreases lipid peroxidation, but 
has no effect on plasma advanced glycated end-products 
in adults with type 2 diabetes: a randomized double-blind 
clinical trial. Food Nutr Res. 2015; 59: 28551, doi: 10.3402/
fnr.v59.28551, indexed in Pubmed: 26355954.
43. Stroop R, Thomale UW, Päuser S, et al. Magnetic resonance 
imaging studies with cluster algorithm for characterization 
of brain edema after controlled cortical impact injury 
(CCII). Acta Neurochir Suppl. 1998; 71: 303–305, indexed 
in Pubmed: 9779214.
44. Sulakhiya K, Kumar P, Gurjar SS, et al. Beneficial effect 
of honokiol on lipopolysaccharide induced anxiety-like 
behavior and liver damage in mice. Pharmacol Biochem 
Behav. 2015; 132: 79–87, doi: 10.1016/j.pbb.2015.02.015, 
indexed in Pubmed: 25725264.
45. Talarek S, Listos J, Barreca D, et al. Neuroprotective effects 
of honokiol: from chemistry to medicine. Biofactors. 
2017; 43(6): 760–769, doi: 10.1002/biof.1385, indexed 
in Pubmed: 28817221.
46. Ucar T, Tanriover G, Gurer I, et al. Modified experimental 
mild traumatic brain injury model. J Trauma. 2006; 60(3): 
558–565, doi:  10.1097/01.ta.0000209172.75637.db, 
indexed in Pubmed: 16531854.
47. Wang H, Liao Z, Sun X, et al. Intravenous administration of 
Honokiol provides neuroprotection and improves functional 
recovery after traumatic brain injury through cell cycle inhi-
bition. Neuropharmacology. 2014; 86: 9–21, doi: 10.1016/j.
neuropharm.2014.06.018, indexed in Pubmed: 24973706.
48. Wang X, Duan X, Yang G, et al. Honokiol crosses BBB and 
BCSFB, and inhibits brain tumor growth in rat 9L intracer-
ebral gliosarcoma model and human U251 xenograft gli-
oma model. PLoS One. 2011; 6(4): e18490, doi: 10.1371/
journal.pone.0018490, indexed in Pubmed: 21559510.
49. Xu Q, Yi LT, Pan Y, et al. Antidepressant-like effects of the 
mixture of honokiol and magnolol from the barks of Mag-
nolia officinalis in stressed rodents. Prog Neuropsychophar-
macol Biol Psychiatry. 2008; 32(3): 715–725, doi: 10.1016/j.
pnpbp.2007.11.020, indexed in Pubmed: 18093712.
50. Yuan TM, Yu HM, Gu WZ, et al. Expression of glial fibrillary 
acidic protein in developing rat brain after intrauterine 
infection. Neuropathology. 2004; 24(2): 136–143, indexed 
in Pubmed: 15139591.
51. Zhang Le, Deng M, Zhou S. Tetramethylpyrazine inhibits 
hypoxia-induced pulmonary vascular leakage in rats 
via the ROS-HIF-VEGF pathway. Pharmacology. 2011; 
87(5-6): 265–273, doi: 10.1159/000326082, indexed in 
Pubmed: 21494058.
52. Zhang P, Liu X, Zhu Y, et al. Honokiol inhibits the inflamma-
tory reaction during cerebral ischemia reperfusion by sup-
pressing NF-kB activation and cytokine production of glial 
cells. Neurosci Lett. 2013; 534: 123–127, doi: 10.1016/j.
neulet.2012.11.052, indexed in Pubmed: 23262090.
53. Zhou PH, Hu W, Zhang XB, et al. Protective Effect of 
Adrenomedullin on Rat Leydig Cells from Lipopolysaccha-
ride-Induced Inflammation and Apoptosis via the PI3K/
Akt Signaling Pathway ADM on Rat Leydig Cells from 
Inflammation and Apoptosis. Mediators Inflamm. 2016; 
2016: 7201549, doi: 10.1155/2016/7201549, indexed in 
Pubmed: 27212810.
